Nimodipino Stadafarma (Nimodipine)

Nimodipine, the active ingredient in Nimodipino Stadafarma, is a calcium channel blocker of the dihydropyridine class presented as an oral tablet for oral administration. It works by selectively antagonising L‑type calcium channels in cerebral vessels, thereby reducing the risk of vasospasm after subarachnoid hemorrhage in adult patients.

GNH USA supplies Nimodipino Stadafarma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory conformity across markets.

Nimodipine acts on cerebral vasculature to prevent vasospasm following subarachnoid hemorrhage.

- Subarachnoid hemorrhage: reduces the incidence and severity of cerebral vasospasm after aneurysmal bleed.

Nimodipine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate pain often reported during therapy. - Dizziness: sensation of light‑headedness, especially when standing quickly. - Hypotension: reduction in blood pressure, may cause faintness. - Nausea: upset stomach or urge to vomit. - Flushing: warm, reddened skin, usually on the face or neck. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Bradycardia: unusually slow heart rate that may be symptomatic. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: severe skin and mucous membrane disorder. - Seizures: rare neurologic events requiring urgent care.

Before initiating Nimodipino Stadafarma, clinicians should consider several safety measures.

- Blood pressure monitoring: check systolic and diastolic values regularly during therapy. - CYP3A4 inhibitors: avoid concomitant use with strong inhibitors to prevent excess drug exposure. - Hepatic impairment: use with caution in patients with liver dysfunction, adjusting dose if necessary. - Pregnancy and lactation: assess risk‑benefit ratio before prescribing to pregnant or nursing women. - Hypersensitivity: discontinue immediately if signs of allergic reaction appear. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Nimodipine can interact with several medicines, influencing its safety and effectiveness.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma levels and increase toxicity. - Concurrent potent vasodilators (e.g., nitroglycerin): additive hypotensive effect can be dangerous. - Grapefruit juice: can elevate nimodipine concentrations, heightening adverse effects.

Moderate Interactions (Monitor Closely): - Other antihypertensives (beta‑blockers, ACE inhibitors): monitor blood pressure for excessive lowering. - Diuretics: watch electrolytes and blood pressure for synergistic effects. - Antiepileptic drugs (phenytoin, carbamazepine): may reduce nimodipine levels, requiring efficacy assessment.